Literature DB >> 27847686

Parkinson disease and cognitive impairment: Five new things.

Albert A Davis1, Brad Racette1.   

Abstract

PURPOSE OF REVIEW: While the distinctive motor symptoms of Parkinson disease (PD) have been described for centuries, cognitive impairment has only recently been recognized as a central feature. Studies have yielded clues to the etiology and natural history of cognitive impairment in PD, but much remains unclear and effective therapies are needed. RECENT
FINDINGS: Longitudinal cohort studies demonstrate that almost all patients with PD will develop dementia if they live long enough. New CSF biomarker and genetic studies suggest that it may soon be possible to forecast and track the progression of dementia in PD. Sleep and sleep disturbance appear to be intrinsically linked with PD, although the implications for individual outcomes and opportunities for intervention are unclear. Multidisciplinary treatment approaches incorporating cognitive training may help to improve outcomes.
SUMMARY: We review several recent advances in understanding the pathophysiology, genetics, and management of cognitive impairment in PD.

Entities:  

Year:  2016        PMID: 27847686      PMCID: PMC5100708          DOI: 10.1212/CPJ.0000000000000285

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  33 in total

1.  Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease.

Authors:  H I Hurtig; J Q Trojanowski; J Galvin; D Ewbank; M L Schmidt; V M Lee; C M Clark; G Glosser; M B Stern; S M Gollomp; S E Arnold
Journal:  Neurology       Date:  2000-05-23       Impact factor: 9.910

2.  GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease.

Authors:  Ignacio F Mata; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Alice Chen-Plotkin; Vivianna M Van Deerlin; Beate Ritz; Rebecca Rausch; Stewart A Factor; Cathy Wood-Siverio; Joseph F Quinn; Kathryn A Chung; Amie L Peterson-Hiller; Jennifer G Goldman; Glenn T Stebbins; Bryan Bernard; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Liana S Rosenthal; Ted M Dawson; Marilyn S Albert; Debby Tsuang; Haley Huston; Dora Yearout; Shu-Ching Hu; Brenna A Cholerton; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian
Journal:  Mov Disord       Date:  2015-08-21       Impact factor: 10.338

3.  Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study.

Authors:  Stephanie Jb Vos; Chengjie Xiong; Pieter Jelle Visser; Mateusz S Jasielec; Jason Hassenstab; Elizabeth A Grant; Nigel J Cairns; John C Morris; David M Holtzman; Anne M Fagan
Journal:  Lancet Neurol       Date:  2013-09-04       Impact factor: 44.182

Review 4.  Sleep disorders in patients with Parkinson's disease: epidemiology and management.

Authors:  J P Larsen; E Tandberg
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Nursing home and end-of-life care in Parkinson disease.

Authors:  Delaram Safarpour; Dylan P Thibault; Cori L DeSanto; Cynthia M Boyd; E Ray Dorsey; Brad A Racette; Allison W Willis
Journal:  Neurology       Date:  2015-07-02       Impact factor: 9.910

6.  Nocturnal sleep enhances working memory training in Parkinson's disease but not Lewy body dementia.

Authors:  Michael K Scullin; Lynn Marie Trotti; Anthony G Wilson; Sophia A Greer; Donald L Bliwise
Journal:  Brain       Date:  2012-08-20       Impact factor: 13.501

7.  APOE ε4 increases risk for dementia in pure synucleinopathies.

Authors:  Debby Tsuang; James B Leverenz; Oscar L Lopez; Ronald L Hamilton; David A Bennett; Julie A Schneider; Aron S Buchman; Eric B Larson; Paul K Crane; Jeffrey A Kaye; Patricia Kramer; Randy Woltjer; John Q Trojanowski; Daniel Weintraub; Alice S Chen-Plotkin; David J Irwin; Jacqueline Rick; Gerard D Schellenberg; G Stennis Watson; Walter Kukull; Peter T Nelson; Gregory A Jicha; Janna H Neltner; Doug Galasko; Eliezer Masliah; Joseph F Quinn; Kathryn A Chung; Dora Yearout; Ignacio F Mata; Jia Y Wan; Karen L Edwards; Thomas J Montine; Cyrus P Zabetian
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

8.  The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.

Authors:  Mariese A Hely; Wayne G J Reid; Michael A Adena; Glenda M Halliday; John G L Morris
Journal:  Mov Disord       Date:  2008-04-30       Impact factor: 10.338

9.  Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.

Authors:  Tessandra Stewart; Changqin Liu; Carmen Ginghina; Kevin C Cain; Peggy Auinger; Brenna Cholerton; Min Shi; Jing Zhang
Journal:  Am J Pathol       Date:  2014-03-11       Impact factor: 4.307

10.  Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.

Authors:  Cristina Nombela; James B Rowe; Sophie E Winder-Rhodes; Adam Hampshire; Adrian M Owen; David P Breen; Gordon W Duncan; Tien K Khoo; Alison J Yarnall; Michael J Firbank; Patrick F Chinnery; Trevor W Robbins; John T O'Brien; David J Brooks; David J Burn; Roger A Barker
Journal:  Brain       Date:  2014-07-30       Impact factor: 13.501

View more
  9 in total

1.  Early Sociability and Social Memory Impairment in the A53T Mouse Model of Parkinson's Disease Are Ameliorated by Chemogenetic Modulation of Orexin Neuron Activity.

Authors:  Milos Stanojlovic; Jean Pierre Pallais Yllescas; Aarthi Vijayakumar; Catherine Kotz
Journal:  Mol Neurobiol       Date:  2019-06-27       Impact factor: 5.590

2.  Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson's disease.

Authors:  Milos Stanojlovic; Jean Pierre Pallais; Michael K Lee; Catherine M Kotz
Journal:  Mol Brain       Date:  2019-10-30       Impact factor: 4.041

3.  The 10-year Landscape of United States-Registered Parkinson Disease Clinical Trials: 2007-2016.

Authors:  Kara J Wyant; Erika Yasuda; Vikas Kotagal
Journal:  Mov Disord Clin Pract       Date:  2018-10-04

4.  Clinical Spectrum, Risk Factors, and Behavioral Abnormalities among Dementia Subtypes in a North Indian Population: A Hospital-Based Study.

Authors:  Suman Kushwaha; Puneet Talwar; Aldrin Anthony; Meena Gupta; Kiran Bala; Rachna Agarwal; Vibha Sharma; Ritushree Kukreti
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2017-07-26

5.  Chemogenetic Modulation of Orexin Neurons Reverses Changes in Anxiety and Locomotor Activity in the A53T Mouse Model of Parkinson's Disease.

Authors:  Milos Stanojlovic; Jean Pierre Pallais; Catherine M Kotz
Journal:  Front Neurosci       Date:  2019-07-30       Impact factor: 4.677

6.  Inhibition of Orexin/Hypocretin Neurons Ameliorates Elevated Physical Activity and Energy Expenditure in the A53T Mouse Model of Parkinson's Disease.

Authors:  Milos Stanojlovic; Jean Pierre Pallais; Catherine M Kotz
Journal:  Int J Mol Sci       Date:  2021-01-14       Impact factor: 5.923

7.  Association of the Polygenic Risk Score With the Probability of Prodromal Parkinson's Disease in Older Adults.

Authors:  Maria I Maraki; Alexandros Hatzimanolis; Niki Mourtzi; Leonidas Stefanis; Mary Yannakoulia; Mary H Kosmidis; Efthimios Dardiotis; Georgios M Hadjigeorgiou; Paraskevi Sakka; Alfredo Ramirez; Benjamin Grenier-Boley; Jean-Charles Lambert; Stefanie Heilmann-Heimbach; Maria Stamelou; Nikolaos Scarmeas; Georgia Xiromerisiou
Journal:  Front Mol Neurosci       Date:  2021-12-21       Impact factor: 5.639

8.  Physical Activity Is Associated with Improved Visuomotor Processing in Older Adults with Moderate and Advanced Glaucomatous Visual Field Defect: A Cross-Sectional Study.

Authors:  Teresa Zwierko; Wojciech Jedziniak; Beata Florkiewicz; Piotr Lesiakowski; Marta Śliwiak; Marta Kirkiewicz; Wojciech Lubiński
Journal:  Int J Environ Res Public Health       Date:  2022-02-03       Impact factor: 3.390

9.  The impact of distinct cognitive dual-tasks on gait in Parkinson's disease and the associations with the clinical features of Parkinson's disease.

Authors:  Halil Onder; Ozge Ozyurek
Journal:  Neurol Sci       Date:  2020-11-04       Impact factor: 3.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.